Logo

Sanofi Presents Results of Tolebrutinib in a P-IIb LTS for Relapsing Forms of Multiple Sclerosis at ECTRIMS 2021

Share this
Sanofi Presents Results of Tolebrutinib in a P-IIb LTS for Relapsing Forms of Multiple Sclerosis at ECTRIMS 2021

Sanofi Presents Results of Tolebrutinib in a P-IIb LTS for Relapsing Forms of Multiple Sclerosis at ECTRIMS 2021

Shots:

  • The P-IIb LTS part A assesses tolebrutinib (5/15/30/60mg/day) in patients with RMS and in Part B- where all participants switched to the 60mg
  • The study demonstrated a reduction in MS disease activity as MRI and showed a favorable 1yrs. tolerability. "Mean EDSS scores across treatment groups ranged from 2.18 to 2.65 at baseline and remained relatively stable over 48 weeks. For the 60/60mg treatment group- mean (SD) score was 2.65 (1.22) at baseline and 2.45 (1.31) at Week 48; low MRI lesion activity in patients who started on or switched to 60mg. 98% of patients remained on treatment in P-IIb extension study @48wks.
  • @48wks. of the extension study- low Gd-enhancing lesions (<0.4) in the 60/60mg arm. Additionally- data from in vitro studies in human microglia extended previous observations that BTK-dependent inflammatory signaling can be modulated by tolebrutinib

Ref: Globe Newswire | Image: Medcity News

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions